


Outstanding Performance; Maintain BUY
Est. Vs. Actual for Q3FY24: Revenue – **INLINE**; EBITDA – **INLINE**; PAT – **INLINE**
Changes in Estimates post Q3FY24
FY25E/FY26E – Revenue: 1%/3%; **EBITDA:** 7%/8%; **PAT:** 8%/10%

Recommendation Rationale

- **Strong Performance:** Jyothy Labs' results were strong and in line with our estimates. Revenue grew 11% YoY (vol. grew 11% - highest among FMCG peers), led by stable growth across categories and channels. Despite increased competitive intensity, the company's focus on increasing/scaling distribution reach and brand investment aided in the overall volume growth. Its gross margins improved notably by 666bps YoY to 49.8%, while EBITDA grew 41% YoY. EBITDA margins improved 374bps YoY to 17.5% despite a 45% YoY increase in ad spend.
- **Maintained EBITDA margins guidance of 16-17% in FY24:** Management reiterated the increased competitive intensity which the company will mitigate through increased ad-spends and increased distribution reach. Moreover, it has maintained the EBITDA margins guidance of 16-17% in FY24.
- **Structural story: JLL's promising future is underpinned by the company's robust and consistent performance over the last several quarters,** driven by a series of strategic initiatives it has undertaken in the recent past. These include: a) Scaling up value offerings through Low Unit Packs (LUPs) and driving the premiumisation agenda, particularly in Detergents and Dishwash segments, b) Expanding into the larger Body Wash segment (Toilet Soap) as opposed to its earlier presence in the niche (natural) segment, thereby broadening its product portfolio, c) The management's strategic efforts to expand its direct distribution reach, targeting an increase from the current 1.1 Mn outlets, in tandem with enhancing on-ground execution through its strong sales force of 3,000 (a threefold increase over FY19) and streamlining the distribution channel.

Sector Outlook: Positive
Company Outlook & Guidance: We maintain our **BUY** rating on the stock based on the company's bright future prospects. We have increased our FY25E/26E EPS estimates by 8%/10% based on the above thesis.

Current Valuation: 40x Dec-25 EPS (Earlier Valuation: 35x Sep-25 EPS).

Current TP: Rs 565/share (Earlier TP: Rs 450/share).

Recommendation With a 10% upside from the CMP, we maintain our long-term **BUY** rating on the stock.

Financial Performance: Jyothy Labs' results were strong and ahead of our/street estimates on the operating front. Revenue grew 11% YoY (vol. grew 11% - highest amongst FMCG peers), led by stable growth across categories and channels. Despite increased competitive intensity, the company's focus on increasing/scaling distribution reach and brand investment aided in the overall volume growth. Its gross margins improved notably by 666bps YoY to 49.8%, while EBITDA grew 41% YoY. EBITDA margins improved 374bps YoY to 17.5% despite a 45% YoY increase in ad spend. PAT grew 35% YoY to Rs 91 Cr.

Guidance: Focus on driving double digit revenue growth led by increase rural specific initiatives, increase ad-spends and distribution expansion. Aiming to achieve Rs 5000 Cr revenue (vs. Rs 2484 Cr in FY3) in a span of four years which implies 15-16% CAGR. It maintains EBITDA margins guidance of 16-17% in FY24 with ad-spends to remain at 8% (% of sales).

Valuation & Outlook: JLL's promising future is underpinned by the company's robust and consistent performance over the last several quarters, driven by a series of strategic initiatives it has undertaken in the recent past. These include: a) Scaling up value offerings through Low Unit Packs (LUPs) and driving the premiumisation agenda, particularly in Detergents and Dishwash segments, b) Expanding into the larger Body Wash segment (Toilet Soap) as opposed to its earlier presence in the niche (natural) segment, thereby broadening its product portfolio, c) The management's strategic efforts to expand its direct distribution reach, targeting an increase from the current 1.1 Mn outlets, in tandem with enhancing on-ground execution through its strong sales force of 3,000 (a threefold increase over FY19) and streamlining the distribution channel. Based on the above thesis we expect the company to deliver healthy Revenue/EBITDA/PAT growth of 14%/30%/31% CAGR over FY23-26E respectively which will elevate the company's overall return profile. We expect its ROE to increase from 15% in FY23 to 23% in FY26.

Key Financials (Consolidated)

(Rs Cr)	Q3FY24	QoQ (%)	YoY (%)	Axis Est.	Variance (%)
Net Sales	678	(7.5)	10.6	680	(0.4)
EBITDA	119	(12.4)	40.6	119	(0.3)
EBITDA Margin (%)	17.5	-97 bps	374 bps	17.5	1 bps
Net Profit	91	(12.6)	34.9	91	(0.5)
EPS (Rs)	2.5	(12.6)	34.9	2.5	(0.5)

Source: Company, Axis Research

 (CMP as of 31st Jan'24)

CMP (Rs)	514
Upside /Downside (%)	10%
High/Low (Rs)	553/180
Market cap (Cr)	18,881
Avg. daily vol. (6m)Shrs '000.	1239
No. of shares (Cr)	37

Shareholding (%)

	Jun-23	Sep-23	Dec-23
Promoter	62.9	62.9	62.9
FIIs	14.0	14.6	14.7
MFs / UTI	12.7	12.3	12.2
Banks / FIIs	0.0	0.0	0.0
Others	10.4	10.2	10.2

Financial & Valuations

Y/E Mar (Rs Cr)	FY24E	FY25E	FY26E
Net Sales	2,820	3,214	3,664
EBITDA	498	595	694
Net Profit	384	460	538
EPS (Rs)	10.5	12.5	14.7
PER (x)	49	41	35
EV/EBITDA (x)	37	31	26
P/BV (x)	11	9	8
ROE (%)	21.9	22.9	23.4

Change in Estimates (%)


Y/E Mar	FY25E	FY26E
Sales	1%	3%
EBITDA	7%	8%
PAT	8%	10%

ESG disclosure Score**

Environmental Disclosure Score	3.26
Social Disclosure Score	21.03
Governance Disclosure Score	78.59
Total ESG Disclosure Score	34.35
Sector Average Total	44.87

Source: Bloomberg, Scale: 0.1-100

**Note: This score measures the amount of ESG data a company reports publicly and does not measure the company's performance on any data point. All scores are based on 2022 disclosures

Relative performance


Source: Ace Equity, Axis Securities

PreetyamTolia

 Research Analyst
 email: preetyam.tolia@axissecurities.in

Suhaneeshome

 Research Associate
 email: suhaneeshome@axissecurities.in

Key Risks to our Estimates and TP

- Prolonged recovery in rural, raw material inflation, and increase in the competitive intensity.

Change in Estimates

	Old Est.		Revised Est.		% Revision	
	FY25E	FY26E	FY25E	FY26E	FY25E	FY26E
Revenue	3,186	3,568	3,214	3,664	1%	3%
EBITDA	558	640	595	694	7%	8%
PAT	424	489	460	538	8%	10%
EPS	11.6	13.3	12.5	14.7	8%	10%

Source: Company, Axis Securities

Results Review

(Rs Cr)	Q3FY23	Q2FY24	Axis Est.	Q3FY24	% Change (Y-o-Y)	% Change (Q-o-Q)	Var (%) Axis Sec Est.
Net Sales	613	732	680	678	10.6	(7.5)	(0.4)
Gross Profit	264	360	331	337	27.7	(6.5)	1.7
Gross Margin (%)	43.1	49.2	48.7	49.8	666 bps	55 bps	103 bps
Employee Expenses	66	77	73	75	13.4	(2.3)	3.1
Ad-spends	42	57	51	61	45.1	5.7	17.9
Other Expenses	72	91	88	83	15.5	(8.9)	(6.1)
EBITDA	84	135	119	119	40.6	(12.4)	(0.3)
EBITDA Margin (%)	13.8	18.5	17.5	17.5	374 bps	-97 bps	1 bps
Oth. Inc	15	13	14	11	(30.6)	(20.0)	(23.8)
Interest	3	1	1	1	(62.9)	1.7	(3.1)
Depreciation	12	12	13	13	5.5	4.2	(0.7)
EO Items	-	-	-	-			
PBT	84	135	119	115	36.7	(14.7)	(3.0)
Tax	17	31	27	24	44.0	(22.0)	(11.3)
Reported PAT	67	104	91	91	34.9	(12.6)	(0.5)
EPS	1.8	2.8	2.5	2.5	34.9	(12.6)	(0.5)

Source: Company, Axis Securities

Financials (Consolidated)

Profit & Loss

(Rs Cr)

Y/E March	FY23	FY24E	FY25E	FY26E
Net sales	2,484	2,820	3,214	3,664
Growth, %	13.2	13.5	14.0	14.0
Other operating income	2	2	2	3
Total income	2,486	2,822	3,217	3,667
Raw material expenses	(1,435)	(1,435)	(1,607)	(1,816)
Employee expenses	(264)	(299)	(341)	(392)
Other Operating expenses	(471)	(590)	(674)	(766)
EBITDA (Core)	316	498	595	694
Growth, %	27.3	57.7	19.4	16.7
Margin, %	12.7	17.7	18.5	18.9
Depreciation	(50)	(51)	(53)	(54)
EBIT	266	447	542	639
Growth, %	39.8	68.2	21.2	18.0
Margin, %	10.7	15.9	16.9	17.4
Other Income	40	47	50	52
Non-recurring Items	7	-	-	-
Pre-tax profit	299	489	586	685
Tax provided	(59)	(105)	(126)	(147)
Net Profit	240	384	460	538
Growth, %	46.2	65.1	19.8	16.9

Source: Company, Axis Securities

Balance Sheet

(Rs Cr)

Y/E March	FY23	FY24E	FY25E	FY26E
Cash & bank	283	491	734	1,016
Debtors	138	156	178	203
Inventory	302	343	391	445
Loans & advances	2	2	2	2
Other current assets	50	50	50	50
Total current assets	775	1,042	1,355	1,716
Investments	-	-	-	-
Gross fixed assets	1,413	1,434	1,456	1,479
Less: Depreciation	(296)	(347)	(400)	(454)
Add: Capital WIP	15	15	15	15
Net fixed assets	1,132	1,102	1,071	1,040
Non-current assets	59	59	59	59
Total assets	2,062	2,298	2,581	2,911
Current liabilities	406	435	469	508
Provisions	71	71	71	71
Total current liabilities	477	506	540	579
Non-current liabilities	34	34	34	34
Total liabilities	511	540	574	612
Paid-up capital	37	37	37	37
Reserves & surplus	1,512	1,720	1,969	2,259
Shareholders' equity	1,551	1,759	2,007	2,298
Total equity & liabilities	2,062	2,298	2,581	2,911

Source: Company, Axis Securities

Cash Flow

(Rs Cr)

Y/E March	FY23	FY24E	FY25E	FY26E
Pre-tax profit	299	489	586	685
Depreciation	50	51	53	54
Chg in working capital	(83)	(30)	(36)	(41)
Total tax paid	(53)	(105)	(126)	(147)
Cash flow from operating activities	213	405	477	552
Capital expenditure	(53)	(21)	(22)	(23)
Chg in marketable securities	-	-	-	-
Cash flow from investing activities	(53)	(21)	(22)	(23)
Free cash flow	160	384	455	529
Equity raised/(repaid)	-	-	-	-
Dividend (incl. tax)	(110)	(176)	(211)	(247)
Cash flow from financing activities	(64)	(176)	(211)	(247)
Net chg in cash	96	207	244	281
Opening cash balance	211	283	491	734
Closing cash balance	283	491	734	1,016

Source: Company, Axis Securities


Ratio Analysis

(%)

Y/E March	FY23	FY24E	FY25E	FY26E
Per Share data				
EPS (INR)	6.3	10.5	12.5	14.7
Growth, %	43.7	65.1	19.8	16.9
Book NAV/share (INR)	42.2	47.8	54.6	62.5
FDEPS (INR)	6.3	10.5	12.5	14.7
CEPS (INR)	7.5	11.9	14.0	16.1
CFPS (INR)	8.0	9.7	11.6	13.6
DPS (INR)	3.0	4.8	5.8	6.7
Return ratios				
Return on assets (%)	12.4	17.9	19.1	19.8
Return on equity (%)	15.0	21.9	22.9	23.4
Return on capital employed (%)	16.0	22.1	23.4	24.1
Turnover ratios				
Asset turnover (x)	2.0	2.3	2.6	2.9
Sales/Total assets (x)	1.2	1.3	1.3	1.3
Sales/Net FA (x)	2.2	2.5	3.0	3.5
Working capital/Sales (x)	0.0	0.0	0.0	0.1
Receivable days	20.2	20.2	20.2	20.2
Inventory days	44.4	44.4	44.4	44.4
Payable days	36.1	38.2	38.6	38.8
Working capital days	12.5	15.0	17.2	19.2
Liquidity ratios				
Current ratio (x)	1.9	2.4	2.9	3.4
Quick ratio (x)	1.2	1.6	2.1	2.5
Valuation				
PER (x)	81.3	49.2	41.1	35.2
PEG (x) - y-o-y growth	1.9	0.8	2.1	2.1
Price/Book (x)	12.2	10.8	9.4	8.2
EV/Net sales (x)	7.5	6.5	5.7	4.9
EV/EBITDA (x)	59.1	37.1	30.6	25.9
EV/EBIT (x)	70.3	41.3	33.6	28.1

Source: Company, Axis Securities

Jyothy Labs Price Chart and Recommendation History



Date	Reco	TP	Research
20-Oct-23	BUY	440	Initiating Coverage
08-Nov-23	BUY	450	Result Update
01-Feb-24	BUY	565	Result Update

Source: Axis Securities

About the analyst**Analyst:** Preeyam Tolia**Contact Details:** preeyam.tolia@axissecurities.in**Sector:** FMCG&Retail**Analyst Bio:** Preeyam Tolia is MBA Finance and CFA Level 1 and part of the Axis Securities Research Team.**About the analyst****Analyst:** Suhanee Shome**Contact Details:** suhanee.shome@axissecurities.in**Sector:** FMCG& Retail**Analyst Bio:** Suhanee Shome is MBA and part of the Axis Securities Research Team..**Disclosures:**

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

1. Axis Securities Ltd. (ASL) is a SEBI Registered Research Analyst having registration no. INH000000297. ASL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. ASL is a subsidiary company of Axis Bank Ltd. Axis Bank Ltd. is a listed public company and one of India's largest private sector bank and has its various subsidiaries engaged in businesses of Asset management, NBFC, Merchant Banking, Trusteeship, Venture Capital, Stock Broking, the details in respect of which are available on www.axisbank.com.
2. ASL is registered with the Securities & Exchange Board of India (SEBI) for its stock broking & Depository participant business activities and with the Association of Mutual Funds of India (AMFI) for distribution of financial products and also registered with IRDA as a corporate agent for insurance business activity.
3. ASL has no material adverse disciplinary history as on the date of publication of this report.
4. I/We, Preeyam Tolia (MBA & CFA L1) and Suhanee Shome (MBA) hereby certify that all of the views expressed in this research report accurately reflect my/our views about the subject issuer(s) or securities. I/We (Research Analyst) also certify that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. I/we or my/our relative or ASL does not have any financial interest in the subject company. Also I/we or my/our relative or ASL or its Associates may have beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of the Research Report. Since associates of ASL are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report. I/we or my/our relative or ASL or its associate does not have any material conflict of interest. I/we have not served as director / officer, employee etc. in the subject company in the last 12-month period. Any holding in stock – No
5. ASL has not received any compensation from the subject company in the past twelve months. ASL has not been engaged in market making activity for the subject company.
6. In the last 12-month period ending on the last day of the month immediately preceding the date of publication of this research report, ASL or any of its associates may have:

Received compensation for investment banking, merchant banking or stock broking services or for any other services from the subject company of this research report and / or; Managed or co-managed public offering of the securities from the subject company of this research report and / or; Received compensation for products or services other than investment banking, merchant banking or stock broking services from the subject company of this research report; ASL or any of its associates have not received compensation or other benefits from the subject company of this research report or any other third-party in connection with this report.

Term & Conditions:

This report has been prepared by ASL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ASL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ASL will not treat recipients as customers by virtue of their receiving this report.

DEFINITION OF RATINGS	
Ratings	Expected absolute returns over 12-18 months
BUY	More than 10%
HOLD	Between 10% and -10%
SELL	Less than -10%
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning valuation and recommendation
UNDER REVIEW	We will revisit our recommendation, valuation and estimates on the stock following recent events
NO STANCE	We do not have any forward looking estimates, valuation or recommendation for the stock

Disclaimer:

Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to the recipient's specific circumstances. The securities and strategies discussed and opinions expressed, if any, in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

This report may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this report should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this report (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. Certain transactions, including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. ASL, its directors, analysts or employees do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of shares and bonds, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ASL and its affiliated companies, their directors and employees may; (a) from time to time, have long or short position(s) in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities or earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or investment banker, lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting this document.

ASL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that ASL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. ASL may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. The Research reports are also available & published on AxisDirect website.

Neither this report nor any copy of it may be taken or transmitted into the United State (to U.S. Persons), Canada, or Japan or distributed, directly or indirectly, in the United States or Canada or distributed or redistributed in Japan or to any resident thereof. If this report is inadvertently sent or has reached any individual in such country, especially, USA, the same may be ignored and brought to the attention of the sender. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ASL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors.

The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The Company reserves the right to make modifications and alternations to this document as may be required from time to time without any prior notice. The views expressed are those of the analyst(s) and the Company may or may not subscribe to all the views expressed therein.

Copyright in this document vests with Axis Securities Limited.

Axis Securities Limited, SEBI Single Reg. No.- NSE, BSE & MSEI – INZ000161633, ARN No. 64610, CDSL-IN-DP-CDSL-693-2013, SEBI-Research Analyst Reg. No. INH 000000297, SEBI Portfolio Manager Reg. No.- INP000000654, Main/Dealing off.- Axis Securities Ltd, Unit No.1001, 10th Floor, Level-6, Q2 Building, Aurum, Q Parc, Plot No. 4/1, TTC, Thane – Belapur Road, Ghansoli, Navi Mumbai. – 400 710., Regd. off.- Axis House,8th Floor, Wadia International Centre, PandurangBudhkar Marg, Worli, Mumbai – 400 025. Compliance Officer: Jatin Sanghani, Email: compliance.officer@axisdirect.in, Tel No: 022-49212706